Evidence map›Paper›PMID 22984144›Full record

ArticleJournal of lipid research2012

Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation.

Kenneth N Ikei, Jennifer Yeung, Patrick L Apopa, Jesús Ceja, Joanne Vesci, Theodore R Holman, Michael Holinstat

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. iScience · 2026
    Article
  3. Article
  4. Impacts of Oxylipins on ischemic stroke: from pathophysiology to clinical phenotypes.Metabolomics : Official journal of the Metabolomic Society · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Deficiency in platelet 12-lipoxygenase exacerbates inflammation and disease severity during SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kenneth N IkeiDepartment of Chemistry and Biochemistry, University of California at Santa Cruz, Santa Cruz, CA, USA.
Jennifer Yeung
Patrick L Apopa
Jesús Ceja
Joanne Vesci
Theodore R Holman
Michael Holinstat
Thomas Jefferson University · USUniversity of California, Santa Cruz · US

Funding

Functional and Inhibitory Studies of Human LipoxygenaseR01GM056062 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HOLMAN, THEODORE R · 2002 to 2012
$3.1M
Thrombin regulation of Rap1 signaling in human platelet activityR00HL089457 · NHLBI · THOMAS JEFFERSON UNIVERSITY · PI HOLINSTAT, MICHAEL ALLAN · 2008 to 2010
$747k
THERMO ELECTRON LTQ-FT MASS SPECTROMETERS10RR020939 · NCRR · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HOLMAN, THEODORE R · 2006 to 2006
$368k
ACQUISITION OF A VARIAN 600 MHZ HIGH-RESOLUTION NMR: CANCERS10RR019918 · NCRR · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI CREWS, PHIL · 2004 to 2004
$272k
FUNCTIONAL STUDIES OF HUMAN AND SOYBEAN LIPOXYGENASER29GM056062 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI HOLMAN, THEODORE R · 1997 to 2001
$206k
Thrombin regulation of Rap1 signaling in human platelet activityK99HL089457 · NHLBI · VANDERBILT UNIVERSITY · PI HOLINSTAT, MICHAEL ALLAN · 2007 to 2008
$180k
NCRR NIH HHS S10 RR019918NCRR NIH HHS S10 RR020939NCRR NIH HHS S10-RR-19918NCRR NIH HHS S10-RR-20939NHLBI NIH HHS HL-089457NHLBI NIH HHS K99 HL089457NHLBI NIH HHS R00 HL089457NIGMS NIH HHS GM-56062NIGMS NIH HHS R01 GM056062NIGMS NIH HHS R29 GM056062
6 · The paper itself

Abstract

Human platelet-type 12-lipoxygenase (12-LOX) has recently been shown to play an important role in regulation of human platelet function by reacting with arachidonic acid (AA). However, a number of other fatty acids are present on the platelet surface that, when cleaved from the phospholipid, can be oxidized by 12-LOX. We sought to characterize the substrate specificity of 12-LOX against six essential fatty acids: AA, dihomo-γ-linolenic acid (DGLA), eicosapentaenoic acid (EPA), α-linolenic acid (ALA), eicosadienoic acid (EDA), and linoleic acid (LA). Three fatty acids were comparable substrates (AA, DGLA, and EPA), one was 5-fold slower (ALA), and two showed no reactivity with 12-LOX (EDA and LA). The bioactive lipid products resulting from 12-LOX oxidation of DGLA, 12-(S)-hydroperoxy-8Z,10E,14Z-eicosatrienoic acid [12(S)-HPETrE], and its reduced product, 12(S)-HETrE, resulted in significant attenuation of agonist-mediated platelet aggregation, granule secretion, αIIbβ3 activation, Rap1 activation, and clot retraction. Treatment with DGLA similarly inhibited PAR1-mediated platelet activation as well as platelet clot retraction. These observations are in surprising contrast to our recent work showing 12(S)-HETE is a prothrombotic bioactive lipid and support our hypothesis that the overall effect of 12-LOX oxidation of fatty acids in the platelet is dependent on the fatty acid substrates available at the platelet membrane.

Indexed as

Arachidonate 12-LipoxygenaseFatty Acids, EssentialHumansOxidation-ReductionPlatelet ActivationSubstrate SpecificityArachidonate 12-LipoxygenaseFatty Acids, Essential

Identifiers

PMID22984144
PMCPMC3494251
OpenAlexW2152443396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.